Article
Endocrinology & Metabolism
Tsung-Cheng Hsieh, Guang-Hong Deng, Yung-Ching Chang, Fang-Ling Chang, Ming-Shan He
Summary: This study aimed to investigate optical coherence tomography (OCT) biomarkers of diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy. The results showed that partially continuous inner segment-outer segment (IS-OS) layers were predictive of better response, while epiretinal membrane (ERM) was a significant predictor of poor response.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Ophthalmology
Justis P. Ehlers, Steven Yeh, Maureen G. Maguire, Justine R. Smith, Prithvi Mruthyunjaya, Nieraj Jain, Leo A. Kim, Christina Y. Weng, Christina J. Flaxel, Scott D. Schoenberger, Stephen J. Kim
Summary: Evidence review suggests that anti-VEGF agents and corticosteroids are effective treatments for diabetic macular edema, but corticosteroid therapy may lead to elevated intraocular pressure and cataract progression. Further research is needed to compare the efficacy of these therapies and individualized treatment choices are essential for optimal outcomes.
Article
Ophthalmology
Ali Salimi, Natalia Vila, Milad Modabber, Michael Kapusta
Summary: This study investigated the anatomical and functional changes associated with Aflibercept treatment in Bevacizumab nonresponders with chronic DME in a Canadian setting. The results highlighted the efficacy of Aflibercept as an alternative therapeutic option for DME recalcitrant to Bevacizumab, with potential additional benefit to those with worse vision, greater CST, and better glycemic control at baseline.
INDIAN JOURNAL OF OPHTHALMOLOGY
(2021)
Review
Ophthalmology
Kian Madjedi, Austin Pereira, Brian G. Ballios, Parnian Arjmand, Peter J. Kertes, Michael Brent, Peng Yan
Summary: For patients with refractory diabetic macular edema, switching to alternative anti-vascular endothelial growth factor (VEGF) agents such as aflibercept or ranibizumab may lead to significant improvement in retinal thickness and edema.
SURVEY OF OPHTHALMOLOGY
(2022)
Article
Medicine, General & Internal
Jeeyoung Kwak, You Hyun Lee, Kyung Tae Kang, Yu Cheol Kim
Summary: This retrospective study compared the effectiveness of intravitreal bevacizumab (IVB) injections alone and during cataract surgery in patients with diabetic macular edema. It found that in patients who underwent cataract surgery after IVB injection, there was a significant decrease in central subfield macular thickness.
JOURNAL OF CLINICAL MEDICINE
(2023)
Letter
Ophthalmology
Vikas Ambiya, Sandeep Shankar, Ashok Kumar, Dubbaka Srujana
Summary: A case of ocular toxoplasmosis as a rare complication of intravitreal dexamethasone implant in a patient with diabetic macular edema is reported. The patient developed toxoplasma retinochoroiditis involving the macula 3 weeks after the injection, but his vision improved after antibiotic treatment.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Medicine, General & Internal
Eugene Yu-Chuan Kang, Sunir J. Garg, Hsi-Fu Chen, Wei-Chi Wu, Linda Yi-Hsing Chen, Hung-Da Chou, Laura Liu, Kuan-Jen Chen, Yih-Shiou Hwang
Summary: Intravitreal dexamethasone (DEX) implants are effective in treating refractory uveitic macular edema (ME), with significant improvements in visual acuity (VA) and central retinal thickness (CRT) observed after one month of the first implantation. Further studies are needed to assess the long-term outcomes and effects of multiple implants.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Stephanie Baillif, Pascal Staccini, Michel Weber, Marie-Noelle Delyfer, Yannick Le Mer, Vincent Gualino, Laurence Collot, Pierre-Yves Merite, Catherine Creuzot-Garcher, Laurent Kodjikian, Pascale Massin
Summary: In this multicenter retrospective observational study, switching from dexamethasone implant to fluocinolone acetonide implant was found to be effective and safe in treating diabetic macular edema eyes. A short time between the switch was associated with reduced central macular thickness fluctuations and the need for early additional treatments.
Article
Ophthalmology
Dilsher S. Dhoot, Hadi Moini, Kimberly Reed, Weiming Du, Robert Vitti, Alyson J. Berliner, Rishi P. Singh
Summary: This study aimed to assess the time to, cumulative incidence of, and functional benefit of achieving sustained improvement in diabetic macular oedema (DMO) in terms of the Diabetic Retinopathy Severity Scale (DRSS). The results showed that patients treated with intravitreal aflibercept injections achieved sustained improvement in DRSS earlier and more frequently compared to laser treatment, and this improvement was associated with greater improvement in visual acuity, independent of central subfield thickness reduction.
Review
Pharmacology & Pharmacy
Roberta Spinetta, Francesco Petrillo, Michele Reibaldi, Antonia Tortori, Maria Mazzoni, Cristian Metrangolo, Francesco Gelormini, Federico Ricardi, Antonio Giordano
Summary: This review examines the use of intravitreal dexamethasone implants (DEX) in the treatment of diabetic macular edema (DME) and highlights the lack of unified agreement among retina specialists from different countries. The findings provide a broader perspective and global understanding of the topic.
Article
Medicine, Research & Experimental
Angelo Maria Minnella, Stefano Maria Picardi, Martina Maceroni, Francesca Albanesi, Elisa De Siena, Giorgio Placidi, Carmela Grazia Caputo, Umberto De Vico, Stanislao Rizzo, Benedetto Falsini
Summary: The study evaluated the morpho-functional outcomes of intravitreal fluocinolone acetonide (FAc) implant, showing significant improvements in anatomical and functional outcomes related to retinal layers affected by diabetic retinopathy. These findings suggest that the FAc implant may have a protective effect in diabetic retinas with diabetic macular edema.
ADVANCES IN THERAPY
(2021)
Article
Pharmacology & Pharmacy
Alaa Din Abdin, Wissam Aljundi, Khalil El Jawhari, Shady Suffo, Isabel Weinstein, Berthold Seitz
Summary: The study aimed to evaluate the morphological and functional outcomes of intravitreal brolucizumab treatment for refractory neovascular age-related macular degeneration (nAMD) in the first year. Results showed that brolucizumab could stabilize visual acuity and reduce the number of injections. It also improved anatomical outcomes by reducing subretinal fluid and pigment epithelial detachment. However, adverse events such as intraocular inflammation were observed.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Jia-Kang Wang, Tzu-Lun Huang, Yung-Ray Hsu, Pei-Yao Chang
Summary: This study compared the efficacy and safety of Dexamethasone implant between treatment-naive and refractory Asian patients with diabetic macular edema. The results showed that DEX implant effectively treated both refractory and treatment-naive patients with DME, with superior visual outcomes observed in the treatment-naive group. The study also found that there were no serious ocular complications, and elevated intraocular pressures were manageable with topical medications in a quarter of the patients.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Stefano Ranno, Stela Vujosevic, Manuela Mambretti, Cristian Metrangolo, Micol Alkabes, Giovanni Rabbiolo, Andrea Govetto, Elisa Carini, Paolo Nucci, Paolo Radice
Summary: This study evaluates the role of vitrectomy with or without internal limiting membrane (ILM) peeling in nontractional refractory diabetic macular edema (DME). The results show significant improvements in central macular thickness and visual acuity after vitrectomy. Better outcomes are observed in patients with subfoveal serous retinal detachment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Ophthalmology
Farhad Fazel, Mohammad Malekahmadi, Awat Feizi, Behrooz Oliya, Mehdi Tavakoli, Mohammadreza Fazel
Summary: This study investigated the efficacy of combining suprachoroidal triamcinolone acetonide (SCTA) with intravitreal bevacizumab (IVB) in patients with center-involving diabetic macular edema (CI-DME). The results showed that the combination of SCTA and IVB had significant improvements in both visual acuity and retinal thickness, with no significant side effects observed.
